Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1408948 | 1.00 | GSR (0.50) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL4352729 | 0.93 | GSR (0.59) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL16192990 | 0.93 | GSR (0.59) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL169864 | 0.93 | GSR (0.59) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL14811921 | 0.91 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL29075853 | 0.88 | GSR (0.52) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL1537223 | 0.88 | GSR (0.52) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL997560 | 0.88 | GSR (0.52) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL680614 | 0.84 | GSR (0.59) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL9902389 | 0.83 | GSR (0.47) | GSRDPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423137-B1 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARM INC (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1423137-A4 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARM INC (US) | 2005-11-30 | — | — | EP | claimed |
| EP-1423137-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | Cubist Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | claimed |
| US-20030096948-A1 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | ADOLOR CORPORATION | 2003-05-22 | — | — | US | claimed |
| WO-2003017924-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARMACEUTICALS, INC. (US) | 2003-03-06 | — | — | WO | claimed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20230111132-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| EP-4081254-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021133742-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-2298790-A1 | Daptomycin analogs as antibacterial agents | Cubist Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295444-A2 | Lipopeptides as antibacterial agents | Cubist Pharmaceutical Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-1423137-B1 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARM INC (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1246838-A1 | LIPOPEPTIDES AS ANTIBACTERIAL AGENTS | Cubist Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1240181-A2 | DAPTOMYCIN ANALOGS AS ANTIBACTERIAL AGENTS | Cubist Pharmaceuticals, Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020058785-A1 | Novel lipopeptides as antibacterial agents | MERCK SHARP & DOHME CORP. | 2002-05-16 | — | — | US | disclosed |
| US-20020025924-A1 | Novel lipopeptides as antibacterial agents | MERCK SHARP & DOHME CORP. | 2002-02-28 | — | — | US | disclosed |
| WO-2001044272-A2 | DAPTOMYCIN ANALOGS AS ANTIBACTERIAL AGENTS | CUBIST PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044274-A1 | LIPOPEPTIDES AS ANTIBACTERIAL AGENTS | CUBIST PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-5914313-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5741775-A | ANTIBIOTIC AND ANTIFUNGAL AGENTS | MERCK & CO., INC. (US) | 1998-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058785-A1 | Novel lipopeptides as antibacterial agents | CLPTM1, NGLY1, VIP | GSR 3234/4885DPP7 456/4885DPP4 437/4885 |
| US-20030096948-A1 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | LSS, NGLY1, RPN1 | GSR 3978/4885DPP7 252/4885DPP4 491/4885 |
| US-20020025924-A1 | Novel lipopeptides as antibacterial agents | CLPTM1, NGLY1, VIP | GSR 3234/4885DPP7 456/4885DPP4 437/4885 |
| US-20230111132-A1 | STABILIZATION OF MHC COMPLEXES | MICA, CD74, HLA-DRB1 | GSR 2408/4885DPP7 3085/4885DPP4 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.